<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03114319</url>
  </required_header>
  <id_info>
    <org_study_id>CTNO155X2101</org_study_id>
    <secondary_id>2016-001861-10</secondary_id>
    <nct_id>NCT03114319</nct_id>
  </id_info>
  <brief_title>Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors</brief_title>
  <official_title>An Open-label, Multi-center, Phase I, Dose Finding Study of Oral TNO155 in Adult Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this first in human (FIH) trial is to characterize the safety and tolerability
      of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a
      recommended dose for future studies in adult patients with advanced solid tumors in selected
      indications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study has been designed as a Phase I, open-label, dose finding study with a dose
      escalation part and a dose expansion part in adult patients with selected advanced solid
      tumors. The study treatment, TNO155 alone or in combination with EGF816 (nazartinib), will be
      taken until the patient experiences unacceptable toxicity, progressive disease and/or
      treatment is discontinued at the discretion of the investigator or the patient or due to
      withdrawal of consent. Some patients will be participating in a food effect investigation as
      an exploratory objective.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2017</start_date>
  <completion_date type="Anticipated">August 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>up to 5 years; at least once per treatment cycle</time_frame>
    <description>All patients participating in this study will be assessed for incidence and severity of adverse events (AEs) and serious AEs, including changes in laboratory values, vital signs, electrocardiograms, cardiac imaging and ophthalmological assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with dose limiting toxicities</measure>
    <time_frame>up to 28-day cycle</time_frame>
    <description>Incidence and nature of dose limiting toxicities (DLTs) in the dose escalation part. A DLT is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first treatment cycle (either 21 days or 28 days, depending on the cohort's treatment schedule) with TNO155 or with TNO155 in combination with EGF816 (nazartinib)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>From start of treatment for 60 months</time_frame>
    <description>To evaluate the preliminary anti-tumor activity of TNO155 or of TNO155 in combination with EGF816 (nazartinib), e.g., overall response rate per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pERK</measure>
    <time_frame>At screening and between Cycle 1 and Cycle 3 on treatment for 60 months</time_frame>
    <description>On treatment versus baseline comparison of pharmacodynamic markers e.g., pERK (Phosphorylated form of Extracellular signal-regulated kinase) on newly obtained tumor samples by IHC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve</measure>
    <time_frame>60 months</time_frame>
    <description>Area under the plasma concentration time curve of TNO155</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>60 months</time_frame>
    <description>highest observed plasma concentration of TNO155</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>60 months</time_frame>
    <description>Time of highest observed plasma concentration of TNO155</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apparent terminal elimination half-life</measure>
    <time_frame>60 months</time_frame>
    <description>terminal elimination half-life of TNO155</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve</measure>
    <time_frame>60 months</time_frame>
    <description>Area under the plasma concentration time curve of TNO155 and EGF816 (nazartinib) when given in combination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>60 months</time_frame>
    <description>highest observed plasma concentration of TNO155 and EGF816 (nazartinib) when given in combination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>60 months</time_frame>
    <description>Time of highest observed plasma concentration of TNO155 and EGF816 (nazartinib) when given in combination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apparent terminal elimination half-life</measure>
    <time_frame>60 months</time_frame>
    <description>terminal elimination half-life of TNO155 and EGF816 (nazartinib) when given in combination</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">255</enrollment>
  <condition>Advanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal SquamousCellCancer (SCC),Head/Neck SCC,Melanoma</condition>
  <arm_group>
    <arm_group_label>TNO155</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TNO155 for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TNO155 in combination with EGF816 (nazartinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TNO155 in combination with EGF816 (nazartinib) in patients with advanced EGFR mutant NSCLC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNO155</intervention_name>
    <description>TNO155 for oral administration</description>
    <arm_group_label>TNO155</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNO155 in combination with EGF816 (nazartinib)</intervention_name>
    <description>TNO155 for oral administration; EGF816 (nazartinib) for oral administration</description>
    <arm_group_label>TNO155 in combination with EGF816 (nazartinib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to understand and voluntarily sign the ICF and able to comply with the study
             visit schedule and the other protocol requirements.

          2. Patient (male or female) ≥18 years of age willing to agree to not father a
             child/become pregnant and comply with effective contraception criteria.

          3. Must have progressed following standard therapy, or for whom, in the opinion of the
             Investigator, no effective standard therapy exists, is tolerated or is appropriate.

          4. ECOG (Eastern cooperative oncology group) performance status ≤2

             Additional criteria only appying to TNO155 in combination with EGF816 (nazartinib):

          5. Patients must be screened for Hepatitis B virus and Hepatitis C virus

        Exclusion Criteria:

          1. Tumors harboring known activating KRAS, NRAS, HRAS, BRAF or PTPN11 (SHP2) mutations.
             (Exceptions are KRAS G12-mutant NSCLC's)

          2. History or current evidence of retinal vein occlusion (RVO) or current risk factors
             for RVO.

          3. Any medical condition that would, in the investigator's judgment, prevent the
             patient's participation in the clinical study due to safety concerns or compliance
             with clinical study procedures.

          4. Clinically significant cardiac disease.

          5. Active diarrhea or inflammatory bowel disease

          6. Insufficient bone marrow function

          7. Insufficient hepatic and renal function.

             Additional criteria only appying to TNO155 in combination with EGF816 (nazartinib):

          8. Patients with a known history of human immunodeficiency virus (HIV) seropositivity.

          9. Patients receiving concomitant immunosuppressive agents or chronic corticosteroids use
             at the time of study entry.

         10. Patients who have undergone a bone marrow or solid organ transplant

         11. Patients with a history or presence of interstitial lung disease or interstitial
             pneumonitis

         12. Bullous and exfoliative skin disorders at screening of any grade

         13. Presence of clinically significant ophthalmological abnormalities that might increase
             the risk of corneal epithelial injury
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>trialandresults.registries@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dana Farber Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Annese</last_name>
      <phone>617-643-1820</phone>
      <email>rannese2@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Geoffrey Shapiro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Murielle Georges</last_name>
      <phone>656-888-4563</phone>
      <email>georgesm@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Helena Yu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Smith</last_name>
      <phone>615-329-7274</phone>
      <email>andrea.smith10@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Melissa Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de LLobregat</city>
        <state>Catalunya</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 11, 2017</study_first_submitted>
  <study_first_submitted_qc>April 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TNO155</keyword>
  <keyword>SHP2</keyword>
  <keyword>advanced solid tumor</keyword>
  <keyword>NSCLC</keyword>
  <keyword>HNSCC</keyword>
  <keyword>Esophageal SCC</keyword>
  <keyword>Melanoma</keyword>
  <keyword>EGFR</keyword>
  <keyword>KRAS G12C</keyword>
  <keyword>GIST</keyword>
  <keyword>PTPN11</keyword>
  <keyword>cancers with a mass</keyword>
  <keyword>bulky tumor</keyword>
  <keyword>nodule</keyword>
  <keyword>lump</keyword>
  <keyword>advanced solid malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>(R,E)-N-(7-chloro-1-(1-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-1H-benzo(d)imidazol-2-yl)-2-methylisonicotinamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

